US Edition9 Articles
9 Articles
Novo Nordisk, Deep Apple Therapeutics ink pact to develop oral therapeutics for Cardiometabolic Diseases
South San Francisco: Deep Apple Therapeutics, Inc. has announced a research collaboration and exclusive worldwide license agreement with Novo Nordisk to discover, develop, and commercialize oral small...
Deep Apple Therapeutics announces collaboration with Novo Nordisk to discover and develop oral therapies for cardiometabolic diseases
Deep Apple Therapeutics Announces Collaboration with Novo Nordisk to Discover and Develop Oral Therapeutics for Cardiometabolic Diseases
Partnership aims to develop first-in-class, small molecule therapeutics directed at a novel non-incretin GPCR target for cardiometabolic diseases Deep Apple is eligible to receive up to $812 million, including an upfront payment, research costs, and milestone payments SOUTH SAN FRANCISCO, Calif., June 11, 2025 /PRNewswire/ -- Deep Apple Therapeutics, Inc. announced today a research collaboration and exclusive worldwide license agreement with Nov…
Novo signs $812 million weight-loss drug license deal with US biotech Deep Apple
Denmark’s Novo Nordisk is partnering with biotech company Deep Apple Therapeutics in a deal worth up to $812 million to develop drugs for cardiometabolic diseases, including obesity, the California-based company said on Wednesday. Deep Apple discovers drug candidates using its AI-based platform that screens virtual libraries of billions of compounds to cut drug discovery time, […] The post Novo signs $812 million weight-loss drug license deal wi…
Novo Nordisk close to title as Europe's most valuable companyNovo Nordisk is just a few billion away from once again taking first place as Europe's most valuable company. This is shown by an overview from Companiesm
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium
